Engineering Iridium Nanoclusters for Boosting Ferroptotic Cell Death by Regulating GPX4 and p53 Functions
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202404895 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Xiaoyu Cui und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Fisheries and Life Science, Shanghai Ocean University, Shanghai, 201306, P. R. China. Hauptthemen laut MEDLINE: Ferroptosis, Phospholipid Hydroperoxide Glutathione Peroxidase, Tumor Suppressor Protein p53, Iridium. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Brain Science and Brain-like Research Programme, Shanghai Sixth People's Hospital, Shanghai, Shanghai Rising-Star Program.
Abstract (Originalsprache)
Emerging evidence indicates that modulating glutathione peroxidase 4 (GPX4) to induce ferroptosis is a promising strategy for tumor treatment. However, most of the GPX4 small molecule inhibitors face limitations due to their poor delivery efficacy and low specificity of ferroptosis activation. Herein, a ferroptosis‐inducing nanomedicine is developed that integrates nutlin‐3 with iridium oxide nanoclusters (NUT‐IrO x NCs) for enhanced ferroptosis‐driven multimodal therapeutic efficacy in colorectal cancer (CRC). This NUT‐IrO x NCs can induce glutathione (GSH) depletion via enhanced Ir (VI)‐Ir (III) transition, while nutlin‐3, a well‐established inhibitor of the p53‐MDM2 interaction, suppresses GSH production by modulation of the p53/SLC7A11/xCT signaling pathway. The reduction of intracellular GSH results in pronounced reductions of GPX4 enzymatic activity, consequently leading to lipid peroxidation accumulation and further enhancing ferroptosis‐induced CRC therapy. This dual‐pronged approach demonstrates robust anticancer therapeutic effects with favorable biocompatibility in both in vitro and in vivo CRC models. This study provides an effective strategy that highlights the benefits of inhibiting of GSH/GPX4 by activating multiple ferroptosis regulatory pathways, providing an alternative therapeutic avenue for CRC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Fisheries and Life Science, Shanghai Ocean University, Shanghai, 201306, P. R. China.
- Department of Ultrasound in Medicine, Shanghai Institute of Ultrasound in Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong, University School of Medicine, Shanghai, 200233, P. R. China.
- Shanghai Key Laboratory of Neuro-Ultrasound for Diagnosis and Treatment, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, P. R. China.
ORCID-Profile: Jianrong Wu
Förderung
- National Natural Science Foundation of China
- Brain Science and Brain-like Research Programme, Shanghai Sixth People's Hospital, Shanghai
- Shanghai Rising-Star Program
Zitieren
APA
Cui, X., Chen, B., Chen, Y., Zhou, M., Cao, L., Hu, B., Wu, J., Ma, X., & Ying, T. (2025). Engineering Iridium Nanoclusters for Boosting Ferroptotic Cell Death by Regulating GPX4 and p53 Functions. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202404895
Vancouver
Cui X, Chen B, Chen Y, Zhou M, Cao L, Hu B, et al. Engineering Iridium Nanoclusters for Boosting Ferroptotic Cell Death by Regulating GPX4 and p53 Functions. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202404895
BibTeX
@article{Cui2025,
author = {Cui, Xiaoyu and Chen, Bin and Chen, Ying and Zhou, Mi and Cao, Lijun and Hu, Bing and Wu, Jianrong and Ma, Xinxin and Ying, Tao},
title = {Engineering Iridium Nanoclusters for Boosting Ferroptotic Cell Death by Regulating GPX4 and p53 Functions},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202404895}
}
EUVIMED